- Home
- CLDX vs MNKD Comparison
CLDX vs MNKD Comparison
Compare CLDX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- MNKD
- Stock Information
- Founded
- CLDX N/A
- MNKD 1991
- Country
- CLDX United States
- MNKD United States
- Employees
- CLDX N/A
- MNKD N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- MNKD Health Care
- Exchange
- CLDX Nasdaq
- MNKD Nasdaq
- Market Cap
- CLDX 1.3B
- MNKD 1.1B
- IPO Year
- CLDX 2008
- MNKD 2004
- Fundamental
- Price
- CLDX $23.36
- MNKD $4.03
- Analyst Decision
- CLDX Buy
- MNKD Buy
- Analyst Count
- CLDX 9
- MNKD 4
- Target Price
- CLDX $50.00
- MNKD $9.75
- AVG Volume (30 Days)
- CLDX 1.1M
- MNKD 3.3M
- Earning Date
- CLDX 08-07-2025
- MNKD 08-06-2025
- Dividend Yield
- CLDX N/A
- MNKD N/A
- EPS Growth
- CLDX N/A
- MNKD 228.27
- EPS
- CLDX N/A
- MNKD 0.10
- Revenue
- CLDX $7,559,000.00
- MNKD $297,595,000.00
- Revenue This Year
- CLDX N/A
- MNKD $13.72
- Revenue Next Year
- CLDX N/A
- MNKD $15.21
- P/E Ratio
- CLDX N/A
- MNKD $38.81
- Revenue Growth
- CLDX 24.49
- MNKD 32.50
- 52 Week Low
- CLDX $14.40
- MNKD $3.51
- 52 Week High
- CLDX $47.00
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- CLDX 64.61
- MNKD 55.90
- Support Level
- CLDX $20.76
- MNKD $3.73
- Resistance Level
- CLDX $23.55
- MNKD $3.83
- Average True Range (ATR)
- CLDX 1.22
- MNKD 0.16
- MACD
- CLDX 0.20
- MNKD 0.05
- Stochastic Oscillator
- CLDX 95.29
- MNKD 98.11
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.